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1. Introduction
Renal cell carcinoma (RCC) affects more than 200.000 people annually worldwide resulting in
102.000 deaths each year. Men are twice as frequently affected as women; population aged
between 50 and 70 years is most frequently affected. Obesity, hypertension, tobacco smoking
and certain occupational exposures have been shown to increase one’s risk for developing
RCC. Rarely RCC develops as a part of the familiar syndrome (e.g. von Hippel-Lindau) [1,2].
Treatment of renal cell carcinoma has changed dramatically over the past few years. Until 2005
cytokine therapy (interferon (IFN-α) or interleukin (IL-2)) was the only (IFN-α) or interleukin
(IL-2) was the only available treatment for mRCC patients. Treatment with cytokines was
associated with little clinical benefit together with substantial side effects; even treatment
related deaths were not infrequent. Treatment options for second line therapy were very
limited; patients could be treated only with another cytokine or best supportive care. Re‐
sponses to second line cytokine therapy were modest. Fewer than 4% of patients had partial
response and < 12% had stable disease [2,3].
Lack of effective therapy together with better knowledge about the cancer biology led to the
development of new targeted agents. Since the start of the “targeted era” development of
new therapies evolved swiftly. Better treatment results in the first line therapy are allied to
the better outcome of the patients on subsequent lines of treatment. Prognosis of patients
improved and mRCC is becoming more a chronic type of disease,  rather than a rapidly
progressing and fatal one [3].
Despite rapid progress in development of new treatments, many questions still remain
unanswered. Patients on targeted therapies progress some time during their treatment and
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mRCC is considered an incurable disease [4]. In trying to overcome this, the mechanism of
action and especially mechanisms of resistance to targeted therapies, need to be studied and
explained even more in detail [3-7].
In this chapter evidence on sequential therapy after progression to the first line will be
presented with the emphasis on changing mechanism of action. Additionally, mechanisms of
resistance to targeted therapies and therapeutic options to overcome resistance will be
discussed.
2. Molecular biology of renal cell carcinoma
Most of the knowledge about molecular biology comes from the studies of a hereditary form
of renal cell carcinoma. Studies of families with inherited RCC over the past twenty years lead
to the identification of five inherited renal cancer syndromes and their related genes. Descrip‐
tion of all five syndromes is beyond the scope of this chapter; only Von Hippel-Lindau
syndrome will be explored [2].
2.1. Von Hippel-Lindau tumor suppressor gene
The von Hippel-Lindau (VHL) disease is a rare, autosomal dominantly inherited disease.
Individuals with this syndrome are predisposed to development of multiple benign and
malignant tumors. Most common are clear cell renal tumors, retinal and central nervous system
hemangioblastomas, pheocromocytomas, pancreatic neuroendocrine tumors, endolymphatic
sac tumors and pancreatic and kidney cists. VHL occurs in 1 in 36.000 and symptomatic disease
develops in 70% of affected persons by the age of 60 years. Bilateral RCC develop in 25-45%
of VHL patients. VHL results from mutation in the von Hippel-Lindau gene on chromosome
3p25-26. The VHL gene discovered in 1993 is a tumor suppressor gene; both copies of gene
must be inactivated for tumor initiation. Different germline mutations predisposing to VHL
include; large deletions, protein-truncating mutations and missense mutations that exchange
the amino acids in the VHL protein. More than 1000 different mutations have been identified
until now. According to the type of mutation, patients are classified in different groups,
predisposed to different types of tumors. Group of patients bearing deletions or nonsense
mutations, most often develop RCC [2,8].
The research on VHL gave light to the inside of molecular biology of sporadic kidney cancer.
It is known, that loss of VHL function, including somatic mutations and epigenetic defects, is
found in 70–90% of the sporadic clear cell RCC [8]. The pathophysiologic mechanism of such
strong association is currently not very understood [8,9].
The VHL protein pVHL has several functions. The most studied is its role in the regulation of
hypoxia inducible factor (HIF1α), member of transcription factors family. At normal cellular
oxygen levels, pVHL binds to HIF1α and causes its degradation. In low oxygen or in the case
when VHL gene is mutated pVHL does not bind to HIF1α. Consequently HIF1α dimerise with
HIF1β and activate the transcription of genes involved in vessel development (vascular
endothelial growth factor, platelet-derived growth factor B, erythropoietin) and genes
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involved in glucose uptake and metabolism. Up-regulation of targeted genes involved in neo-
vascularization by HIF1α offers the explanation of high vascularity of RCC [2,8]. Beside this,
pVHL has numerous other functions in the processes of regulation of extracellular matrix,
senescence, phosphorylation enhancers and other. The importance of many physiologically
relevant functions of pVHL is at present difficult to interpret [8].
Besides VHL, six other genes have been found to predispose to RCC (MET, FLCN, FH, SDH,
TSC 1 and TSC 2). These genes interact trough common nutrient and energy sensing pathways.
Understanding of the molecular mechanisms by which these genes interact in these pathways
has enabled the development of targeted therapies [2].
2.2. VEGF-R pathway
Loss of both alleles of VHL gene leads to up-regulated transcription of growth factors such as
VEGF, PDGF and TGF-α. These factors bind to their tyrosine kinase receptors. This leads to
downstream signalling and ultimately to effects such as increased angiogenesis, increased cell
proliferation and decreased apoptosis. As described previously pVHL mutations are inevita‐
bly connected to flawed HIF inactivation which results in production of VEGF. VEGF is the
most prominent angiogenesis regulator. Its function is mediated through two tyrosine kinase
receptors VEGF-R1 and VEGF-R2 in vascular endothelial cells. VEGF in the beginning binds
to VEGF-R2, which promotes endothelial cell proliferation, migration and vascular permea‐
bility. In the next step VEGF binds to VEGF-R1 to assist the organization of new capillaries [9].
2.3. mTOR pathway
mTOR is another regulator of HIF 1α, its signalling activity increases the cellular levels of HIF
1α, which worsens the already high levels of it because of absence of pVHL function. mTOR
is a serine/threonine kinase that has a key function in apoptosis, cell growth and tumor
proliferation. mTOR forms complexes with regulatory associated proteins named mTORC1
and mTORC2. mTORC 1 can be activated by growth factors including VEGFR, PDGFR, EGFR
and IGFR and nutrients trough phosphatidylinositol-3 kinase/Akt (PI3K/Akt) pathway.
Activated mTORC1 stimulate protein synthesis, entrance into G 1 phase, and proteins that
regulate apoptosis [9].
3. Development of systemic therapy in mRCC
3.1. Chemotherapy
The successes on other solid tumors led researches to the assumption chemotherapy would be
effective also in mRCC. Chemotherapeutic trials were conducted between 1983 and 1993.
Different agents; bleomycin, cisplatin, 5-FU, gemcitabine and vinblastine have been tested.
Results were disappointing; less than 10% of patients had clinical benefit in all of these trials.
Response rates in the range of 10 to 15% have been achieved with combination of two agents.
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Today chemotherapy has no role in the treatment of mRCC patients and is not part of the
everyday clinical practice [2].
Several mechanisms have been discovered to be responsible to the resistance of RCC cells to
chemotherapy. Beside increased detoxification, altered targets and impaired apoptosis
pathways, increased expression of transporting proteins play an important role. P-glycopro‐
tein is a 170-kD membrane glycoprotein that acts as a pump that expels chemicals like
vinblastine out of the cell [2].
3.2. Cytokines
The interest in interferon in the treatment of RCC came when sporadic responses in patients
with RCC on leucocyte interferon, were observed. Natural interferon produced from donor’s
leucocytes, was later substituted with recombinant. Different forms and dosages were tested
and no major differences between them were observed. Uniformly response rates ranged from
0 to 29% with few complete and very few durable responses. Some trials suggested that certain
group of patients have larger benefit (good performance status, prior nephrectomy and
restricted metastases to the lungs), but this was not a uniform finding. Today interferon as
mono-therapy is not widely used, because of the low efficacy coupled with high toxicity [2].
IL-2 was discovered in 1979 and it soon became clear that it could be effective in the treatment
of RCC. Response rates of 33% have been reported in the initial trials. Later multicentric trials
reported response rates in 7-19% of patients. In small number of patients responses were
complete and durable; 7-9% of all patients did not relapse even after 10 years and these patients
are considered to be cured from cancer. Unfortunately until today the selection of patients
likely to have durable responses is not possible, because patient and tumor characteristics that
predict best responses to IL-2 have not been identified yet [2]. Beside uncertain responses,
unfavourable toxicity profile limits the use of IL-2. Patients treated with high doses of IL-2 may
experience vascular leak syndrome, hypotension, multiorgan dysfunction and a variety of
other toxicities. In the two decades, when IL-2 was the standard therapy of mRCC patients
were selected on safety bases (performance status, co-morbidities), tumor histology (clear cell),
risk scores (e.g. Memorial Sloan Kettering Cancer Center) and patient preferences [2,10].
3.3. VEGF targeted therapy
It  is  not  surprising that  several  agents  targeting VEGF demonstrate activity in RCC. As
described  in  previous  sub  chapter  there  is  direct  link  between  VHL  mutation  and  up
regulation of angiogenesis- promoting proteins including VEGF and PDGF. VEGF is the
main factor responsible for tumor angiogenesis and PDGF is signalling protein for perycites,
structural supporting cells for blood vessels. VHL is mutated in most of the patients with
RCC [2,10,11].
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3.3.1. Sunitinib
Sunitinib is a potent multi-kinase inhibitor including platelet-derived growth factor receptor
(PDGFR) α and β, stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT-3), VEGF
receptors 1,2,3, colony stimulating factor (CSF-1R) and neurotropic factor receptor. Large
multicentric phase 3 trial in which 750 patients were randomized in a 1:1 fashion between
treatment with IFN-α and sunitinib, demonstrated its superiority over IFN-α. Overall response
rate was 31% in the sunitinib and 6% in the IFN group (p<0.0001).The median PFS in the
sunitinib group was 11 and in IFN-α 5 months. Difference was observed also in overall survival
(median 26.8 months in sunitinib and 21.8 months in the IFN group, p=0.051). The most
common adverse events were fatigue, diarrhea, mucositis, hand-foot syndrome and hyper‐
tension [12,13]. Sunitinib was approved by FDA in 2007 and is today standard of care in the
first-line treatment of mRCC [2,9].
3.3.2. Pazopanib
Pazopanib is an oral multitargeted tyrosine kinase inhibitor that targets VEGFR 1,2,3, PDGFR
α and β and c-KIT. Approval of pazopanib in 2009 was based on a phase III trial in which 435
patients were randomized (2:1) to receive either pazopanib 800 mg once daily or placebo. The
median PFS of 9.2 months in the pazopanib group was significantly longer than in placebo
group where PFS was 4.2 months (p<0.0001). Main side effects were diarrhoea in half, hyper‐
tension in 40% and nausea, anorexia, vomiting and fatigue in 20% of patients [14]. Grade 3
hepatotoxicity was also reported. Pazopanib is recommended in the first line treatment of
mRCC [2,14].
3.3.3. Bevacisumab
Bevacisumab is a recombinant monoclonal antibody that binds circulating VEGF protein and
neutralizes it [15]. In the AVOREN trial 649 previously untreated patients were randomized
to receive either bevacisumab every two weeks and IFN-α or placebo and IFN-α. Differences
in PFS (10.2 vs. 5.4 months) and ORR (31 vs. 13%) were significantly better in bevacisumab
group (p<0.0001 for both parameters) [16]. The second trial conducted by Cancer and Leukemia
Group B was similar. PFS of 8.5 months in the bevacisumab was statistically significant better
than in the IFN monotherapy group (PFS 5.2 months, p<0,0001). Differences were also
demonstrated comparing ORR favoring bevacisumab group (25.5 vs. 13.1% p<0,0001). Fatigue,
anorexia, hypertension and proteinuria were among the most common side effects and more
prominent in the combination group [2,11,16,17].
3.3.4. Sorafenib
Sorafenib is a small molecule, oral multikinase inhibitor that inhibits VEGFR 1,2,3, PDGFR-β,
RAF, serine/threonine intracellular kinase, FLT-3, cKIT and RET. Sorefenib was tested in a
phase III trial (TARGET), 903 patients with mRCC resistant to standard therapy were random‐
ized to receive sorafenib twice daily or placebo. PFS in the sorafenib group was 5.5 months
and in placebo group 2.8 months (p<0.000001). Difference in OS did not reach statistical
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significance. Major side effects of sorafenib were rash, hand-foot syndrome, fatigue, diarrhoea
and hypertension [18].
3.3.5. Axitinib
Axitinib is a second line inhibitor of VEGFR 1 and 2 and is approved in the second line
treatment of mRCC. Axitinib was compared to sorafenib in a phase III trial (AXIX). 723 patients
previously treated with suntinib, bevacisumab plus IFN, temsirolimus or cytokines that
progressed, were randomized to receive axitinib or sorafenib 400 mg. Median PFS in the
axitinib group was 6.7 months and was statistically significant better than in sorafenib group
(4.7 months, p<0.0001). Patients in axitinib group had more hypertension, diarrhoea, dyspho‐
nia, fatigue and nausea, while patients in sorafenib had more hand foot syndrome, rash and
alopecia [19].
3.4. mTOR targeted therapy
Abnormal functioning of signaling pathways contributes to many malignancies including
RCC [20-22]. The mammalian target of rapamycin (mTOR) is a protein kinase that regulates
cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription
[2]. The disruption of mTOR signaling leads to suppression of the production of proteins that
regulate progression of the cell trough the cell cycle and angiogenesis [22].
3.4.1. Temsirolimus
Temsirolimus, an mTOR inhibitor was approved for the treatment of mRCC in the 2007. Global
Advance Renal Cell Carcinoma (ARCC) was a phase III trial of temsirolimus in previously
untreated mRCC. Patients were randomized to receive either IFN-α, temsirolimus or both. PFS
in the groups receiving temsirolimus was significantly longer than in the IFN group (3.7
months in temsirolimus groups vs. 1.9 months in the IFN group; p=0.0019). Patients treated
with temsirolimus alone had better overall survival than patients treated with IFN alone (10.9
months vs. 7.3 months, p=0.096). Toxicity was greater in the combination group and included
rash, stomatitis, pain, infection, peripheral edema, thrombocytopenia, hyperlipidemia,
hypercholesterolemia and hyperglycemia [20].
3.4.2. Everolimus
Everolimus is an oral mTOR inhibitor approved for the treatment of mRCC in the second line
after progression on sunitinib or sorafenib. Everolimus treatment was tested in phase III trial
named RECORD-1. 410 patients which had progressed to previous treatment were randomly
assigned to receive either everolimus or placebo. Median PFS in the everolimus group was 4.9
months, in placebo group 1.9 months (p<0.001). The median OS was not significantly different
between the two groups (14.8 in everolimus and 14.4 in placebo group, p=0.126) The most
common side effects of everolimus were stomatitis, rash, fatigue, asthenia and diarrhea [21,22].
Summary of phase III trials is presented in Tables 1 and 2.
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4. Mechanism of resistance to targeted therapies
Large advances in treatment results achieved with targeted therapies in mRCC are remarkable,
but still between a third and two-thirds of patients with mRCC have tumors refractory to anti-
VEGF and mTOR inhibitors from the beginning of treatment and all patients develop drug
resistance and relapse some time during the course of their disease. Research of the mecha‐
nisms of resistance is very important in planning the development of new targeted agents [3,
23,24]. Most of information about drug resistance in mRCC known today is from the preclinical
studies or studies on patients with different types of cancer, where targeted therapies are being
in clinical practice for longer time (e.g. breast cancer). This is partially due to the rapid approval
of targeted agents in mRCC which surpassed understanding of the mechanisms of response
and resistance [3].
Until now two types of resistance to targeted therapy have been determined, so called intrinsic
and extrinsic resistance [3].
Author Name Treatment Arm Prior Therapy
Sunitninib Motzer et.al.(2007)
Sunitinib
IFN-α None
Pazopanib Sternberg et.al.(2010)
Pazopanib
Placebo None or Cytokine
Bevacisumab Escudier et.al.(2007) AVOREN
Bevacisumab plus IFN-α
Placebo plus IFN-α None
Sorafenib Escuder et.al.(2006) TARGET
Sorafenib
Placebo Cytokine
Axitinib Rini et.al.(2011) AXIS
Axitinib
Sorafenib
Sunitinib or
Bevacisumab+IFN or
temsirolimus or
cytokines
Everolimus Motzer et.al.(2008) RECORD-1
Everolimus
Placebo Sunitinib or Sorafenib
Temsirolimus Hudes et.al.(2007) ARCC
Temsirolimus
IFN-α
Temsirolimus plus IFN-α
None
Table 1. Phase III trials of targeted agents in mRCC
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4.1. Intrinsic resistance
Intrinsic resistance (primary resistance) occurs when tumor does not respond to the targeted
therapy from the beginning of the treatment. Lack of the clinical benefit, even a short-lasting
one is observed in these patients. Roughly 25% of patients are resistant to therapy; no response
is detected on first evaluation after 2-3 months [23]. This type of resistance has not been
explained entirely jet.
In the case of the resistance to VEGF inhibitors and TKI-s pre-existing pro-angiogenic factors,
such as fibroblast growth factor-2 promote tumor angiogenesis. Pre-existence of pro-angio‐
genic factors compensate for the inhibition of VEGF signaling and thus allow angiogenesis to
continue [3,23]. Pre-existing inflammatory cells may also contribute to the angiogenesis by
expressing pro-angiogenic factors. In pre-clinical trials mRCC tumors that were not responsive
Objective
Response Rate
Progression Free
Survival Overall Survival
Most Common Adverse
Events of Experimental
Drug
Sunitninib 31% Sunitinib6% IFN
11 months Sunitinib
5 months IFN
P<0.0001
26.4 months Sunitinib
21.8 months IFN
P=0.051
Diarrhea, fatique, nausea,
stomatitis, vomiting
Pazopanib 30% Pazopanib3% Placebo
9.2 months Pazopanib
4.2 months Placebo
P<0.0001
21.1 months Pazopanib
18.7 months Placebo
Diarrhea, hypertension,
hair color change, nausea,
anorexia
Bevacisumab 31% Bev+IFN 13%Placebo+IFN
10.2 months Bev+IFN
5.4 months Placebo+IFN
P<0,0001
23.3 months Bev+IFN
21.3 months Placebo
+IFN
P=0.13
Fatique, pyrexia, anorexia,
bleeding, asthenia
Sorafenib 10% Sorafenib2% Placebo
5.5 months Sorafenib
2.8 months Placebo
P<0,01
17.8 months Sorafenib
15.2 months Placebo
P=0.15
Diarrhea, rash, fatigue,
hand-foot syndrome
Axitinib 19% Axitinib9% Sorafenib
6.7 months Axitinib
4.7 months Sorafenib
P<0.001
Not reported
Diarrhea, hypertension,
fatigue, decreased apetite,
nausea
Everolimus 1% Everolimus0% Placebo
4.9 months Everolimus
1.9 months Placebo
P<0,0001
14.8 months Everolimus
14.4 months Placebo
P=0.177
Stomatitis, rash, fatigue,
asthenia, diarrhea
Temsirolimus
8.6% Tem
4.8% IFN
8.1% Tem+IFN
3.7 months Tem
1.9 months IFN
3.7 months Tem+IFN
P=0.0001 (between Tem
and IFN)
10.9 months Tem
7.3 months IFN
8.4 months Tem+IFN
P=0.08 (between Tem
and IFN)
Asthenia, rash, anemia,
nausea, anorexia
Table 2. Phase III trials of targeted agents in mRCC
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to anti-VEGF antibody were associated with increase in infiltrating CD11b + GR1 + myeloid
cells, which expressed several pro-angiogenic factors [23].
The proposed mechanisms of resistance to inhibitors of mammalian target of rapamycin
(mTOR) include the presence of redundant signaling pathways, presence of KRAS or BRAF
mutations, loss of phosphatase and tension homologue deleted on chromosome ten (PTEN),
low cellular levels of p27 or 4E-bp1 and overexpression of eIF4E [3].
Intrinsic resistance to anti-angiogenic factors and mTOR inhibitors is widespread and leads to
poor patient outcome. Alternative pathways should be considered in this patients such as
targeting RAF and MEK or PI3K/AKT. Including patients with resistant tumors in clinical trials
testing these new agents that target these pathways is strongly recommended [23].
4.2. Extrinsic resistance
All  patients  who  initially  have  clinical  benefit  of  targeted  therapy  eventually  develop
resistance to it and experience disease progression. This resistance, named extrinsic resist‐
ance  (also  known  as  secondary,  evasive,  acquired  or  adaptive  resistance)  has  been  ex‐
plained more  in  detail  [23].  TKI  and VEGF inhibitors  both  target  components  of  VEGF
signaling pathway. Thus the mechanisms involved will affect any of these targeted agents.
Extrinsic resistance results from the acquisition of adaptive mechanisms to the action of
angiogenesis inhibitors which ultimately results in evasion of the angiogenesis and reemer‐
gence of tumor-related vasculature [3,25].
Sprouting of new vessels has been detected in Xenograft RCC tumors resected shortly after
the start of sunitinib. The development of resistance is constantly preceded by restoration of
blood flow, which suggests that new vasculature is less dependent (but not necessary inde‐
pendent) of VEGF [25].
4.2.1. Up-regulation of pro-angiogenic factors
Different pro-angiogenic factors involved in the mechanism of resistance to targeted agents
have been recognized. In a mouse model of pancreatic neuroendocrine cancer, resistant tumors
expressed high levels of FGF 1, 2, ephrin A1, angiopoetin and interleukin-8 [23,25]. Inhibition
of these proteins was shown to inhibit tumor growth of resistant RCC-s [25].
Interleukin-8 (IL-8) is a potent pro-angiogenic factor. Up-regulation of IL-8 plays an important
role in RCC resistance. In a xenograft model of RCC mimicking clinical resistance to sunitinib,
increased IL-8 secretion from tumors was associated with reactivation of tumor angiogenesis
and administration of IL-8 neutralizing antibody lead to re-sensitization to sunitinib. Elevated
IL-8 expression was also found in patients with tumors who did not respond to sunitinib from
the beginning [5,22]. IL-angiogenic signaling may functionally compensate for the inhibition
of VEGF/VEGFR-mediated angiogenesis [5].
Angiopoetin 2 (Ang-2) is a plasma glycoprotein involved in angiogenesis and cancer neovas‐
cularization. It is thought to have a role in development of the resistance. Levels of Ang-2
decrease after the initiation of sunitinib treatment and increase after the resistance occurs [23].
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Sphingosine kinase (S1P) is also supposed to play a role in the resistance. S1P is an enzyme
that catalyzes the formation of sphingosine-1-phosphate which is associated with cell prolif‐
eration, survival and angiogenesis. Plasma levels of S1P decrease after the start of sunitinib
treatment and increase again upon the development of resistance. In pre-clinical models
administering neutralizing antibodies against S1P to mice, delayed the growth of sunitinib-
resistant tumors [23].
4.2.2. Down-regulation of angiostatic factors
Down-regulation of angiostatic factors is another mechanism of resistance to TKI-s. Treatment
with sunitinib and sorafenib results in the increased expression of several IFN-inducible genes
including the angiostatic chemokines CXCL 10 and CXCL 11 and tumor suppressor genes.
Following the development of resistance, the expression of IFN-γ and several of IFN-inducible
genes is reduced. Down regulation of these factors is associated with the development of
resistance to sunitinib and sorafenib [23].
4.2.3. Recruitment of bone marrow-derived cells
Recruitment of bone marrow-derived cells which can result in the development of new blood
vessels is another possible mechanism of resistance. In pre-clinical studies recruitment of
CD11b + GR1 + myeloid cells cells resulted in resistance development. There is also evidence
that tumor vasculature can be protected from anti-angiogenic therapy by increased pericyte
coverage [23].
4.2.4. Development of invasion without angiogenesis
Invasion of tumor in normal tissue and recruitment of normal tissue vasculature protect the
tumors from anti-angiogenic therapy. It has been reported that the tumor of a patient experi‐
encing disease progression during antiangiogenic therapy had invaded the surrounding tissue
and there had been increase of the vascularization from the normal tissue to the center of the
tumor [23].
4.2.5. Resistance to m-TOR inhibitors
Resistance to mTOR inhibitors is far less explained. It is supposed to be the result of activation
of feedback loops that promote the activation of molecular signaling pathways of survival,
increased activity of mTOR-complex 2, up-regulation of insulin-like growth factor and increase
in the ERK/MAPK pathway signaling [4,24,25].
4.2.6. Reversible resistance
Preclinical studies revealed that resistance to VEGF targeted therapies can be reversible.
Hammers and colleagues grafted skin metastases of mRCC patient who had become resistant
to sunitinib into mice and these xenogafts regained sensitivity and responded to sunitinib.
Histology of original skin metastasis and xenograft revealed that a reversible epithelial-to-
mesenchymal transition could be responsible for acquired resistance to sunitinib. Zhang
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concluded that reversible changes in gene expression within the tumor cells and/or their
microenvironment could be the possible mechanism of reversible resistance. He implanted
sorafenib-resistant RCC into mice and after implantation tumors regained the sensitivity to
sorafenib [4,25].
4.2.7. Mechanism of resistance to different targeted agents
In the case of sunitinib, the proposed mechanism of resistance is the activation or up-regulation
of alternative angiogenic signals (e.g. FGF-s, ephrins, andiopoetins) while in the case of
sorafenib this mechanism seem to be recruitment of pro-angiogenic bone marrow-derived cells
and monocytes. Recruitment of perycites that help to maintain vessels permeable and func‐
tional and prevent endothelial cells from being affected by antiangiogenic therapies, is the
proposed mechanisms of resistance to pasopanib. In the case of bevacisumab resistance the
increased potential of tumor cells to invade without the need of neovascularization is supposed
to be the mechanism [4,9,25].
5. Overcoming the resistance
Overcoming the resistance to first line therapy is one of the aims of administering the second
line and beyond. Several factors play important role in selection of second line strategy: clinical
evidence, toxicity issues and individual patient profile [4,25,26].
Sequential use of targeted agents is currently the standard of care for mRCC patients. This
approach enables patients to get most benefit from these agents avoiding the excessive toxicity
associated with combination therapy [26-28]. Targeted agent in the second line can have the
same or different mechanism of action as first-line one. Limited data suggest that the use of a
TKI after the failure of another TKI is reasonable and that there is not complete cross-resistance
of these agents. The hypothesis behind this is that although TKIs share the same mechanism
of action, their molecular targets are different. Despite this, the evidence of this approach is
not strong; prospective, phase III trials are missing. Changing mechanism of action can have
several advantages: greater chance of overcoming resistance while decreasing the probability
of cumulative toxicity [4,25]. Toxicities of TKI-s and mTOR inhibitors for example, differ
considerably. Frequent grade 3 toxicities encountered in patients on TKI-s are hand-foot
syndrome, diarrhoea, fatigue, hypertension, neutropenia and leukopenia, while grade 3
toxicities in patients treated with mTOR inhibitors are rash, stomatitis, pneumonitis, anemia
and infection [25-30].
5.1. TKI-s following cytokine therapy
The almost historical treatment strategy where changing of mechanism of action proved to be
effective was TKI-s following cytokines. Currently this approach is not of clinical use anymore,
because most of the patients get molecular targeted agent in the first line; however it is likely
that some patients will have been treated with a cytokine previously. Phase III trials demon‐
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strated that this approach is effective and safe and become a basis of approval of sunitinib and
pazopanib in the first line treatment [3].
5.2. Combinations of targeted agents
Combinations of targeted agents could be in theory effective mechanism to overcome the
resistance because we could combine agents with different mechanisms of action. However
combining these therapies may increase the incidence of side effects if the combination drugs
are not selected carefully [29]. Most of patients do not tolerate full doses of two VEGF inhibitors
at the same time. That is the reason why administering combination therapy long enough to
surpass the clinical benefit of subsequent mono-therapy is not possible [25].
Combinations of VEGF-TKI and mTOR inhibitors also lead to unacceptable toxicity. In a trial
of Patel et.al, combination of temsirolimus and sunitinib lead to dose limiting toxicity in 2 of
3 patients [31]. Data suggest that the side effects and tolerability of combinations correlate with
the total number of inhibited targets. This is the explanation why some combinations with
VEGF specific agent bevacisumab may be tolerated (e.g. bevacisumab plus everolimus). At
present combination of targeted agents in the treatment of mRCC is not recommended in
clinical practice mainly because of excessive toxicity [23,29].
5.3. Second VEGF-TKI after the first line VEGF-TKI
Retrospective and prospective phase II trials showed that treatment with second TKI could be
beneficial in patients that progressed on first TKI. At first sight this may seem not logical, but
variations in kinase targets and interaction may avoid resistance. However definitive data from
phase III trials on this topic are still missing. Benefit of the second TKI after the first TKI may
be dependent on its relative potency and selectivity profile [9]. Most of the results from
retrospective and small prospective trials suggest that patients with mRCC who progress on
sorafenib could benefit from sunitinib. Conversely the use of sorafenib after sunitinib or
bevacisumab showed limited efficacy [9,27].
Sabin et.al. evaluated 68 patients treated with sunitinib and sorafenib consequently. ORR was
better when the patients received sorafenib first; 15% in the group that received sunitinib
followed by sorafnib group and 9% in the group that received sorafenib after sunitinib. Median
PFS in the first group was 12.4 months (6 months on sorafenib and 6.4 months on sunitinib)
and 8.9 months in the second group (5 months on sunitinib and 3.9 months on sorafenib) [26].
Porta et.al evaluated retrospectively 99 patients treated with sunitinib followed by sorafenib
(SuSo) and 90 patients treated with sorafenib followed by sunitnib (SoSu). The median PFS of
second line treatment in the first group (SuSo) was 7.9 months and in the second group was
4.2 months (SoSu) [32]. Clinical trial in progress NCT00732914 with the aim to evaluate if total
PFS of sorafenib followed by sunitinib is superior compared to sunitinib followed by sorafenib
is expected to give some additional light to this issue [3].
AXIS trial directly compared the efficacy and safety of axitinib to sorafenib after progression
on sunitinib, bevacisumab, temsirolimus or cytokines. In the subpopulation of patients who
previously received sunitinib, median PFS was 4.8 months with axitinib and 3.4 months with
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sorafenib (p=0,001). Shorter median PFS in both arms receiving first line sunitinib compared
to those receiving cytokines (median PFS 12.1 in axitinib and 6.5 moths in sunitinib) suggest
that at least partial cross-resistance with sequential TKI-s [3,9,19].
Reduced clinical efficacy of second line therapy as a result of cross resistance is key concern
associated with the sequential administration of agents targeting the same molecular path‐
ways. Two prospective trials showed that because of the cross-resistance, sorafenib had limited
efficacy in patients who progressed on sunitinib or bevacisumab [27].
Another concern about using sequential VEGF-TKI therapies is toxicity. Although they may
differ in toxicity profiles, all TKI-s share similar targets and exhibit class effect toxicities like
hypertension, hand foot syndrome and rash [9]. Current data suggest that Switching to agents
with different mechanisms of action in the second line therapy may provide superior efficacy
and reduced cumulative toxicity [27].
5.4. VEGF-TKI after first line anti VEGF
Very limited data are available on the use of TKI-s after progression on bevacisumab and no
clinical trial is currently ongoing to address this issue. Only two minor prospective trials
conducted by Garcia and Rini evaluated the use of sunitinib or sorafenib in patients with
bevacisumab-refractory mRCC [3].
In a phase II trial of Garcia, 48 patients were enrolled. After progression on treatment with
sunitinib or bevacisumab, patients received twice daily 400 mg of sorafenib. One unconfirmed
objective partial response was observed and the tumor burden reduction rate was 30%. The
median PFS was 4.4 months. There was no association of PFS and tumor shrinkage with
response to prior therapy. Most treatment-related adverse events were of mild-to-moderate
intensity, and included fatigue, hypertension, diarrhoea, and hand-foot syndrome [33].
Rini et.al. conducted a phase II multicentric trial in which patients with mRCC and disease
progression after bevacizumab-based therapy received oral sunitinib 50 mg once daily in 6-
week cycles on a 4/2 schedule (4 weeks with treatment followed by 2 weeks without treatment).
Sixty-one patients were enrolled. The ORR was 23.0%, median PFS was 30.4 weeks and median
OS was 47.1 weeks. Most treatment-related adverse events were of mild-to-moderate intensity
and included fatigue, hypertension, and hand-foot syndrome. Results from measuring
different VEGF-s in the plasma suggest that sunitinib could inhibit some of the signaling factors
involved in bevacisumab resistance [34].
5.5. mTOR inhibitor after first line VEGF-TKI
Another approach in patients who progress on first line TKI-s is to switch to a second line
therapy with an agent with different mechanism of action like mTOR inhibitor [3,9]. On
theoretical basis mTOR inhibitors could overcome the resistance to VEGF-TKIs. VEGF-TKIs
increase tumor hypoxia which results in up-regulation of proangiogenic factors and increase
potential of metastases. mTor inhibition decreases translation of proangiogenic factors and
tumors that have become resistant to VEGF-TKI may respond to treatment with mTOR
Changing Mechanisms of Action as a Strategy for Sequential Targeted Therapy of Metastatic Renal-Cell Carcinoma
http://dx.doi.org/10.5772/55694
199
inhibitor [27]. The evidence of effectiveness of this approach comes from preclinical data. Trial
conducted by Larkin and colleagues compared treatment with sunitinib, sunitinib followed
by sorafenib or sunitinib followed by everolimus in mice implanted with murine RCC.
Sunitinib followed by everolimus was associated with reduced primary tumor weight and
volume in a greater extend compared to tumors treated with sunitinib and sunitinib followed
by sorafenib. The conclusion was that sequential therapy with sunitinib followed by everoli‐
mus is associated with significant anti-tumor and anti-metastatic effect [35].
Everolimus was approved in the second line therapy on results of RECORD-1 trial. In this
double blind, phase III trial, patients who had progressed on first line sunitinib, sorafenib or
both were randomized to everolimus or placebo. Patients receiving everolimus had longer PFS
compared to placebo (4.9 vs. 1.9 months, p<0.001). The clinical benefit of everolimus was
observed regardless if the patients received previously one or two consequent TKI-s. In the
subgroup of patients who received one TKI, median PFS in everolimus group was 5.4 months,
and in group who received two TKI-s 4 months. This was statistically significant longer than
in placebo groups, where PFS was 1.9 and 1.8 months respectively [8,20,36-38].
Prospective head to head trials to compare mTOR inhibitors and VEGF-TKI-s in the second
line of treatment in patients who progressed on the first line VEGF-TKI-s have not been done.
Di Lorenzo and colleagues indirectly compared survival benefit in patients on everolimus or
sorafenib in the second line. Median overall survival was 81.5 weeks for patients receiving
everolimus and 32.0 weeks for sorafenib [37].
The optimal sequencing of sunitinib and everolimus is currently being evaluated in the
RECORD-3 trial and furthermore the everolimus plus bevacisumab in the second line after
progression on TKI-s is currently being compared to everolimus plus placebo in the
NCT01198158 trial [3].
The efficacy and safety of temsirolimus after progression on TKI-s are expected to be revealed
in an ongoing trial NCT00474786, a phase III trial comparing temsirolimus vs. sorafenib in the
second line treatment in patients who have failed on first-line sunitinib. Results from small
population in retrospective and prospective phase II trial presented on ASCO 2010 suggest,
that temsirolimus is safe and effective in pretreated patients, especially those with good
performance status and good prognostic factors [3].
Regarding toxicity mTOR inhibitors and VEGF-TKIs block different molecular mechanisms,
the toxicity profiles are usually not overlapping. In the RECORD-1 trial patients could tolerate
treatment with everolimus after progression on VEGF-TKIs. Stomatitis, infection, asthenia and
fatigue were the most common side effects reported on everolimus therapy. Common toxicities
encountered in the treatment with VEGF-TKIs such as hypertension or hand-foot syndrome,
were not frequent [3,19].
5.6. Alternative scheduling and dosage
A different approach to overcome the resistance can potentially be the change in scheduling
and/or dosage of the targeted agent in usage. Sunitinib is approved in intermittent schedule
of 4 weeks on drug and 2 weeks off drug. Continuous low-dose therapy has been shown to be
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a feasible treatment option in first and second line of treatment [37,38]. Comparison between
the two scheduling is currently not very well determined, but clinical and toxicological
differences may in future be important issue in treatment individualization. Another option
is re-challenge with the same drug after discontinuation period on disease progression. The
basis for this approach comes from pre-clinical data that indicate that resistance to sorafenib
is reversed by re-implantation of resistant tumors in untreated mice [23].
The question of optimal treatment dosage becomes particularly relevant on disease progres‐
sion. Meta-analysis of patients with solid tumors receiving sunitinib revealed that patients
receiving higher dose, had longer time to progression compared to patients who received less
sunitinib. Additionally patient receiving higher dose had more complete or partial remissions
and greater decrease in tumor size. In the trial comparing sorafenib with IFN-α, patients in the
sorafenib group received higher dose of sorafenib (600 mg BID) after progression on 400 mg
BID. Reduction of tumor size was observed. Suggested clinical benefit of increased dose after
progression is outweighed by increased toxicity. Most of patients do not tolerate dosage
increase [22].
5.7. Intrinsic resistance
Prognosis of patients who progress early in the course of first line therapy VEGF targeted
therapy is poor. No available agents seem to alter the course of their disease and give them
clinical benefit. 86 patients with rapid progression after first line therapy were evaluated in a
retrospective trial. PFS after second line therapy with treatment with different VEGF-TKI was
2 months and after second line therapy with mTOR 0.9 months (p=0.536). Larger retrospective
trial in which 272 patients were included showed similar results. All patients had rapid disease
progression after first line VEGF-TKIs. The response rates, PFS and OS of those receiving
second-line VEGF-targeted therapy compared with mTOR inhibitors were 10 vs 6%, 2.8 vs.2
months and 7.9 vs. 4.7 months. Differences were not statistically significant [9].
6. Third line and beyond
Small prospective and retrospective trials suggest that changing the mechanism of action in
the third line may restore the sensitivity to the initial treatment [3,9,27,32,39,40]. In the ASCO
meeting in 2010 Ferrari presented the results of a prospective trial that compared the admin‐
istration of everolimus or temsirolimus as third line therapy to good performance status
patients resistant to TKI-s. Median PFS was 6 months and disease control was achieved in 39%
of patients. These results suggest that treatment with mTOR inhibitor in the third line and
further than, could be a potential promising treatment option [40].
Another trial conducted by Di Lorenzo et.al. evaluated sorafenib treatment in the third line
after treatment with sunitinib and mTor inhibitor. Of the 34 patients eligible, 23.5% responded
to third line sorafenib. Desease control was 44%, median PFS was 4 and median OS was 6
months. 47% of patients that responded to first line therapy, responded to third-line sorafenib
while of patients who did not respond to first-line, did not respond also to third-line sorafenib.
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The most common 3/4 grade side effects of third line sorafenib were hand-foot syndrome,
anemia, fatigue, diarrhea and neutropenia. These results show that sorafenib could be
considered in the third line treatment in mRCC patients after the failure on sunitinib and mTOR
inhibitor [41]. Blesious retrospectively evaluated 105 patients in the RECORD-1 trial of whom
36 received a VEGF-TKI after receiving everolimus. Patients that received sunitinib, sorafenib
and dovitinib had median PFS of 8 months, 5.3 months and 12.0 months. A partial response
was reported in 8.6% of patients and 68.8% of patients had stable disease. Median OS was 29.1
months [42].
In a trial of Grunwald efficacy of VEGF-targeted therapies in patients after everolimus-
resistant patients who had progressed on a previous TKI was explored. Patients received
sunitinib, sorafenib, dovitinib or bevacisumab/ IFN therapy after failure of everolimus. Of the
40 patients included 10% had partial response and 55% had stable disease. Median PFS was
5.5 months. Authors conclude that VEGF targeted therapy show promising activity in
everolimus resistant metastatic RCC [43].
Porta et. al. evaluated retrospectively the overall PFS benefit of the sequence VEGF-TKI, mTor
inhibitor, VEGF-TKI sequence. The sequence of sorafenib-mTOR-sunitinib (14 patients) was
compared to the sequence sunitinib-mTOR-sorafenib (26 patients). No significant difference in
PFS was found between the two groups (21.9 months vs 22.8 months). The median PFS for the
three lines of treatment were 11.7 months-5.1 months-9.1 months for the group sorafenib-mTOR-
sunitinib and 14.4 months-4.3 months-3.9 months for sunitinib-mTOR-sorafenib group [44].
The results of these trials suggest that re-challenging strategy of VEGF-TKI in the third line of
treatment after progression on VEGF-TKI in the first and mTOR inhibitors in the second may
be a successful treatment approach. The other observation of these trials is that some patients
have minor benefit from the VEGF-TKI inhibitors in the third compared to the benefit in the
first line. The explanation for this is that probably partial cross-resistance to the VEGF-TKIs
accounts at least to some extent for this. One possible strategy to overcome this resistance is
to use the third-line agent with the ability to broadly inhibit multiple angiogenic pathways in
addition to VEGF signaling [9].
Even if no clinical guidelines exist for the fourth-line targeted therapy, some reports suggest
that patients may gain clinical benefit from the sequences of targeted agents with different
mechanisms of action. 48 months of PFS was achieved in an mRCC patient treated with four
lines of targeted therapies (sunitinib, everolimus, sorafenib, temsirolimus). Despite intensity,
treatment was well tolerated and no cumulative toxicity was present. This case study advocates
that sequential use of sunitinib, everolimus, sorafenib and temsirolimus and show that this
could be effective treatment approach with good toxicity profile [45].
Metastatic RCC patients can get benefit from multiple lines of targeted therapy. Resistance to
VEGF-TKIs and mTOR inhibitors seem to be at least partially reversible and re-challenging
with the inhibitors from the same group in subsequent lines of therapy may be a therapeutic
option if toxicity does not limit it. Tailoring treatment to the particular patient is of utmost
importance [3,9,27,32].
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7. Future directions
The current practice of delivery of sequential monotherapy targeted agents is empirical and
mainly based on non-comparative clinical trials. In treatment refractory patients often practical
issues like route of delivery or physician familiarity with the drug prevail over the scientific
evidence in selecting treatment. Deeper understanding of the biology of response and
resistance to targeted agents will elucidate future way in treatment of mRCC patients. New
multi-targeted inhibitors are being rapidly developed and their role in overcoming resistance
will become clear in the next few years. Together with the developments of these new drugs,
finding predictive biomarkers of these new and “old” therapies is one of the major research
goals [25].
7.1. New targeted agents
Dovitinib is an investigational multi-target inhibitor of FGF receptors 1-3, PDGF receptor,
VEGFrs 1-3 and c-KIT. One of the mechanisms of resistance to VEGF-TKI seems to be hypoxia-
mediated induction of FGF signaling. Dovitinib was tested in a phase II trial in which patients
with mRCC who failed prior treatment with VEGF-TKI or mTOR inhibitor or cytokines.
Median PFS and OS were 5.5 months and 11.8 months in all patients and 6.1 months and 10.2
months in patients treated with previous VEGF-TKI or mTOR inhibitor. The main grade 3
toxicities of dovitinib were nausea/vomiting in 15%, fatigue in 13.6%, asthenia in 13.5%,
diarrhoea in 10.2% and hypertension in 10.2% of patients. Grade 4 hypertriglicemia occurred
in 8.5% of patients [46].
Tivozanib is a potent selective long half-life tyrosine kinase inhibitor targeting VEGFR 1-3. 517
patients were included in a phase III trial published by Motzer et.al at ASCO 2012. Patients
were randomized to receive either tivozanib or sorafenib. Median PFS was 11.9 months for
tivozanib and 9.1 months for sorafenib (p=0.042). Overall response rate was 33% in tivozanib
and 23% in sorafwnib group (p=0.014). Adverse events grade 3 for tivozanib were hyperten‐
sion, diarrhea, fatigue, neutropenia and hand-foot syndrome [47].
7.2. Biomarkers
Predictive biomarkers could help clinicians to determine the best treatment approach [48,49].
Multiple candidate biomarkers of biological tumor activity as well as treatment response and
patient prognosis are being evaluated [49]. However up to date, none of them showed potential
in clinical use. VHL gene status did not correlate with PFS or OS. The reason for this may be
that almost all RCC cancers have VHL silencing and so this marker cannot be selective enough.
Biomarkers in the peripheral blood have also been tested. Results of some trials showed that
patients with mRCC and elevated expression of angiogenic factors have greater benefit from
VEGF-targeted therapies, although other trials yielded inconsistent results. Other types of
predictive markers, like changes in the tumor blood flow measured by MRI during treatment
with targeted agents are being explored [25,48,49].
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8. Conclusion
Despite great improvement in treatment outcomes with targeted agents in mRCC, the fact
remains that complete remissions are rarely achieved and most patients progress and develop
resistance to the treatment. Many questions are still open and at least some of them are expected
to be solved with the on-going and future clinical trials. Intrinsic and extrinsic tumor resis‐
tances are major obstacles in successful long term tumor control and one of the major questions
is the optimal sequencing of treatment. Use of sequential therapy with changing mechanisms
of action is a rational approach to overcome this resistance.
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